ABSTRACT
With differentiated thyroid cancer, the handicap is nonfeasibility and, therefore, nonavailability of any prospective randomized controlled trials for this cancer. Literature has adequate evidence that presence of lymph nodes may not affect the overall survival, although the recurrence-free survival may be affected. So how much is the optimum surgery continues to be a subject that is still debated. The key, therefore, lies in tailoring the therapy to the patient, tumor, center and the surgeon.
